Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.47 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 8/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.37 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.37 |
| ▸ | NPY4R | P50391 | 2/20 | 0.37 |
| ▸ | NPY1R | P25929 | 1/20 | 0.37 |
| ▸ | NPY2R | P49146 | 1/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23268956 | 1.00 | FAP (0.47) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL18909001 | 1.00 | FAP (0.47) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL19708797 | 1.00 | FAP (0.47) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL24068331 | 1.00 | FAP (0.47) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL18823198 | 1.00 | FAP (0.47) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL19387405 | 0.99 | FAP (0.46) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL18823482 | 0.99 | FAP (0.46) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL19750495 | 0.99 | FAP (0.46) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL20340686 | 0.98 | FAP (0.46) | FAPMAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL26412946 | 0.95 | FAP (0.47) | FAPMAP1LC3BSIRT2SIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043670-B2 | Anti-BCMA antibody-drug conjugates and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-07-23 | — | — | US | disclosed |
| US-20230293710-A1 | ANTIBODY-DRUG CONJUGATES AGAINST THE RECEPTOR TYROSINE KINASE EPHA5 | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230062712-A1 | ANTI-ASGR1 ANTIBODY CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11541126-B1 | Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220177583-A1 | CLAUDIN-6 BISPECIFIC ANTIBODIES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-06-09 | — | — | US | disclosed |
| US-11352348-B2 | Splicing modulator antibody-drug conjugates and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-07 | — | — | US | disclosed |
| US-20220162299-A1 | CLAUDIN-6 ANTIBODIES AND DRUG CONJUGATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-05-26 | — | — | US | disclosed |
| US-20220031859-A1 | HERBOXIDIENE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-02-03 | — | — | US | disclosed |
| US-20220023435-A1 | DRUG CONJUGATE COMPRISING QUINOLINE DERIVATIVES | Universite Paris-Saclay (FR) | 2022-01-27 | — | — | US | disclosed |
| US-20210369853-A1 | TARGETED PROTEASE DEGRADATION PLATFORM | EUBULUS BIOTHERAPEUTICS INC. (CN) | 2021-12-02 | — | — | US | disclosed |
| US-20210299269-A1 | SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-09-30 | — | — | US | disclosed |
| US-20200113912-A1 | Methods and Compositions for the Treatment of Disease with Immune Stimulatory Conjugates | SILVERBACK THERAPEUTICS, INC. (US) | 2020-04-16 | — | — | US | disclosed |
| US-10603386-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20200031798-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | ARS Pharmaceuticals, Inc. | 2020-01-30 | — | — | US | disclosed |
| US-20190345186-A1 | CALICHEAMICIN DERATIVES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER INC. (US) | 2019-11-14 | — | — | US | disclosed |
| US-9872918-B2 | Hydroxyl-polymer-drug-protein conjugates | MERSANA THERAPEUTICS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170348424-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| US-9770519-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170119896-A1 | TERMINALLY MODIFIED POLYMERS AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348424-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | FAP 1390/4885MAP1LC3B 309/4885SIRT2 2534/4885 |
| US-20200113912-A1 | Methods and Compositions for the Treatment of Disease with Immune Stimulatory Conjugates | CD74, CD47, CD69 | FAP 1948/4885MAP1LC3B 2383/4885SIRT2 4165/4885 |
| US-11352348-B2 | Splicing modulator antibody-drug conjugates and methods of use | RBM17, RBM22, SF3B1 | FAP 3070/4885MAP1LC3B 3238/4885SIRT2 4071/4885 |
| US-20220162299-A1 | CLAUDIN-6 ANTIBODIES AND DRUG CONJUGATES | EPCAM, LY96, CD2BP2 | FAP 1818/4885MAP1LC3B 3065/4885SIRT2 3462/4885 |
| US-20190345186-A1 | CALICHEAMICIN DERATIVES AND ANTIBODY DRUG CONJUGATES THEREOF | CALD1, CALU, STT3A | FAP 4082/4885MAP1LC3B 188/4885SIRT2 1392/4885 |
| US-20220031859-A1 | HERBOXIDIENE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | CD74, HPGD, HLA-DRB1 | FAP 4011/4885MAP1LC3B 4200/4885SIRT2 1629/4885 |
| US-20220177583-A1 | CLAUDIN-6 BISPECIFIC ANTIBODIES | EPCAM, CD2BP2, LY96 | FAP 1673/4885MAP1LC3B 3413/4885SIRT2 4290/4885 |
| US-20230062712-A1 | ANTI-ASGR1 ANTIBODY CONJUGATES AND USES THEREOF | ASGR1, HAVCR2, FCGR2A | FAP 3499/4885MAP1LC3B 1900/4885SIRT2 3784/4885 |
| US-20220023435-A1 | DRUG CONJUGATE COMPRISING QUINOLINE DERIVATIVES | HRH3, ABCC3, ORC3 | FAP 4591/4885MAP1LC3B 2548/4885SIRT2 499/4885 |
| US-20210299269-A1 | SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | RBM17, RBM22, SF3B1 | FAP 3070/4885MAP1LC3B 3238/4885SIRT2 4071/4885 |
| US-20200031798-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | TLR8, TLR3, TLR5 | FAP 3807/4885MAP1LC3B 1490/4885SIRT2 886/4885 |
| US-12043670-B2 | Anti-BCMA antibody-drug conjugates and methods of use | HNRNPM, CD79B, BCDIN3D | FAP 3311/4885MAP1LC3B 2423/4885SIRT2 4699/4885 |
| US-10603386-B2 | Protein-polymer-drug conjugates | PBRM1, CLTB, BRAP | FAP 1502/4885MAP1LC3B 240/4885SIRT2 2262/4885 |
| US-20210369853-A1 | TARGETED PROTEASE DEGRADATION PLATFORM | PSMB1, MDM2, XIAP | FAP 215/4885MAP1LC3B 730/4885SIRT2 2639/4885 |
| US-20170119896-A1 | TERMINALLY MODIFIED POLYMERS AND CONJUGATES THEREOF | MALT1, ALG1, PRMT3 | FAP 4017/4885MAP1LC3B 727/4885SIRT2 1983/4885 |
| US-20230293710-A1 | ANTIBODY-DRUG CONJUGATES AGAINST THE RECEPTOR TYROSINE KINASE EPHA5 | EPHA5, EPHA3, EPHA1 | FAP 2557/4885MAP1LC3B 3153/4885SIRT2 4882/4885 |
| US-11541126-B1 | Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof | ASGR1, TLR8, HAVCR2 | FAP 3829/4885MAP1LC3B 1500/4885SIRT2 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.